Tumor-to-Nontumor Ratio in BALB/c nu/nu Mice Bearing HER2-Expressing NCI-N87 Xenografts After Intravenous Injection of 124I-PIB-ZHER2:342 and 125I-PIB-Trastuzumab
| Ratio | |||
|---|---|---|---|
| Location | 6 h | 24 h | 72 h |
| 124I-PIB-ZHER2:342 | |||
| Blood | 8 ± 2 | 16 ± 5 | 27 ± 17 |
| Lung | 6 ± 2 | 2.9 ± 1.0 | 5 ± 5 |
| Liver | 5.6 ± 0.6 | 8 ± 3 | 6 ± 2 |
| Spleen | 5.6 ± 0.8 | 4 ± 2 | 3 ± 1 |
| Stomach | 5 ± 3 | 4.5 ± 1.0 | 5 ± 5 |
| Kidney | 1.5 ± 0.3 | 8 ± 1 | 4 ± 1 |
| Salivary gland | 7 ± 2 | NM | NM |
| Muscle | 53 ± 14 | NM | NM |
| 125I-PIB-trastuzumab | |||
| Blood | 0.8 ± 0.4 | 1.2 ± 0.3 | 1.3 ± 0.4 |
| Lung | 2 ± 1 | 2.8 ± 0.2 | 4 ± 1 |
| Liver | 3 ± 1 | 5.1 ± 0.9 | 7 ± 2 |
| Spleen | 2 ± 1 | 4 ± 1 | 7 ± 1 |
| Stomach | 9 ± 2 | 13 ± 3 | 14 ± 2 |
| Kidney | 2.1 ± 0.8 | 3.1 ± 0.5 | 3.9 ± 0.4 |
| Salivary gland | 6 ± 3 | 5.6 ± 0.5 | 6.9 ± 0.7 |
| Muscle | 21 ± 9 | 12 ± 2 | 19 ± 3 |
Data are presented as average of 4 animals and SD. Radioactivity contents in salivary glands and muscle at 24 and 72 h after injection of 124I-PIB-ZHER2:342 were nonmeasurable (NM) (counts per sample were less than 2 times background counts).